Premium
This is an archive article published on April 10, 2021

Pfizer, BioNTech seek U.S. emergency nod for COVID-19 vaccine in adolescents

In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.

US approved vaccines, Covid-19 vaccine, B1617 variant of COVID-19, US vaccine effective against B1617 variant, world news, Indian expressIndia is currently using Serum Institute of India's Covishield and Bharat Biotech's Covaxin, besides small amounts of the Russian-made Sputnik V vaccines, to inoculate its citizens.

Pfizer Inc and its German partner BioNTech SE said on Friday they have requested the US Food and Drug Administration to expand the emergency use of their Covid-19 vaccine in adolescents aged 12 to 15.

In March, the drugmakers said the vaccine was found to be safe, effective and produced robust antibody responses in 12- to 15-year olds in a clinical trial.

Whether Covid-19 vaccines work and are safe to use on children is one of the big questions drugmakers are trying to answer. Inoculating children and young people is considered a critical step toward reaching “herd immunity” and taming the pandemic, according to experts.

The companies plan to request similar rulings by other regulatory authorities globally in the coming days.

Stay updated with the latest - Click here to follow us on Instagram

Latest Comment
Post Comment
Read Comments
Advertisement
Advertisement
Advertisement
Advertisement